Affordable Access

Publisher Website

[PD-L1 expression: An emerging biomarker in non-small cell lung cancer].

Authors
  • Adam, Julien1
  • Planchard, David2
  • Marabelle, Aurélien3
  • Soria, Jean-Charles4
  • Scoazec, Jean-Yves5
  • Lantuéjoul, Sylvie6
  • 1 Département de biologie et pathologie médicales, Gustave-Roussy, 114, rue Edouard-Vaillant, 94805 Villejuif cedex, France; Inserm U981, Gustave-Roussy, 114, rue Edouard-Vaillant, 94805 Villejuif cedex, France. Electronic address: [email protected]. , (France)
  • 2 Département de biologie et pathologie médicales, Gustave-Roussy, 114, rue Edouard-Vaillant, 94805 Villejuif cedex, France; Département de médecine, Gustave-Roussy, 114, rue Edouard-Vaillant, 94805 Villejuif cedex, France. , (France)
  • 3 DITEP Gustave-Roussy, 114, rue Edouard-Vaillant, 94805 Villejuif cedex, France; Inserm U1015, Gustave-Roussy, 114, rue Edouard-Vaillant, 94805 Villejuif cedex, France. , (France)
  • 4 Inserm U981, Gustave-Roussy, 114, rue Edouard-Vaillant, 94805 Villejuif cedex, France; DITEP Gustave-Roussy, 114, rue Edouard-Vaillant, 94805 Villejuif cedex, France; Faculté de médecine, université Paris Saclay, 63, rue Gabriel-Péri, 94276 Le Kremlin-Bicêtre cedex, France. , (France)
  • 5 Département de biologie et pathologie médicales, Gustave-Roussy, 114, rue Edouard-Vaillant, 94805 Villejuif cedex, France; Faculté de médecine, université Paris Saclay, 63, rue Gabriel-Péri, 94276 Le Kremlin-Bicêtre cedex, France. , (France)
  • 6 Département de biopathologie, MESOPATH, centre Léon-Bérard, 28, rue Laënnec, 69008 Lyon, France; Université Joseph-Fourier, Inserm U823, institut Albert-Bonniot, Grenoble, France. , (France)
Type
Published Article
Journal
Annales de Pathologie
Publisher
Elsevier
Publication Date
January 2016
Volume
36
Issue
1
Pages
94–102
Identifiers
DOI: 10.1016/j.annpat.2015.11.004
PMID: 26778219
Source
Medline
Keywords
License
Unknown

Abstract

Therapies targeting immune checkpoints, in particular programmed death 1 (PD-1) and its ligand programmed death ligand 1 (PD-L1), are major new strategies for the treatment of several malignancies including mestatatic non-small cell lung cancer (NSCLC). The identification of predictive biomarkers of response is required, considering efficacy, cost and potential adverse events. Expression of PD-L1 by immunohistochemistry has been associated with higher response rate and overall survival in several clinical trials evaluating anti-PD-1 and anti-PD-L1 monoclonal antibodies. Thus, PD-L1 immunohistochemical companion assays could be required for treatment with some of these therapies in NSCLC. However, heterogeneity in methodologies of PD-L1 assays in terms of primary antibodies and scoring algorithms, and tumor heterogenity for PD-L1 expression are important issues to be considered. More studies are required to compare the different assays, ensure their harmonization and standardization and identify the optimal conditions for testing. PD-L1 expression is likely an imperfect predictive biomarker for patient selection and association with other markers of the tumor immune microenvironment will be probably necessary in the future.

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. This record was last updated on 07/07/2017 and may not reflect the most current and accurate biomedical/scientific data available from NLM. The corresponding record at NLM can be accessed at https://www.ncbi.nlm.nih.gov/pubmed/26778219
Report this publication

Statistics

Seen <100 times